主页 > 医药生命 >
【medical-news】2型糖尿病联合治疗的新目标
FEATURED REVIEW ARTICLE
Journal of Cardiopulmonary Rehabilitation & Prevention. 27(4):193-201, July/August 2007.
McDonnell, Marie E. MD
Abstract:
The current strategy for treating type 2 diabetes mellitus promotes combination therapy to address the 3 major defects in type 2 diabetes mellitus: (1) impaired peripheral glucose uptake (liver, fat, and muscle), (2) excessive hepatic glucose release (with glucagon excess), and (3) insufficient insulin secretion. Providers can prescribe medications that may have advantageous secondary effects in a patient-specific manner. Adjustment for exercise is generally necessary only with insulin and with medications that may allow insulin secretion despite decreasing glucose levels, such as sulfonylurea drugs. Recently, newer oral medications that address [beta]-cell dysfucntion have been designed to avoid hypoglycemia and to "match" nutritional and nonnutritional needs more directly. Incorporating these agents into regimens will likely reduce hypoglycemia and therefore increase the safety and efficacy of exercise as both a treatment and cardiac monitoring strategy for patients with diabetes.
(C) 2007 Lippincott Williams & Wilkins, Inc.
2型糖尿病联合治疗的新目标
目前2型糖尿病的联合治疗有三个主要的缺点：（1）使外周葡萄糖摄入减少（肝，脂肪和肌肉），（2）使肝糖释放增加（伴糖原增加），（3）使胰岛素分泌不足。从病人角度考虑，医生在处方药物时会权衡利弊。在应用胰岛素和磺脲类药物（降糖的同时促进胰岛素的分泌）时，调整运动是非常必要的。最近，新的口服药物不仅可以改善B细胞功能，还可以减少低血糖，更直接地满足营养和非营养的需要。联合这样的药物，不仅可以减少低血糖，还可以增加运动的安全性和有效性。既可以用于治疗，还可以用于心脏的监测。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-27 17:12
医学,生命科学网